nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolasetron—CYP2C9—Bexarotene—hematologic cancer	0.0399	0.0597	CbGbCtD
Dolasetron—CYP2D6—Lomustine—hematologic cancer	0.0339	0.0508	CbGbCtD
Dolasetron—CYP2C9—Idarubicin—hematologic cancer	0.033	0.0495	CbGbCtD
Dolasetron—CYP2D6—Idarubicin—hematologic cancer	0.0302	0.0453	CbGbCtD
Dolasetron—CYP2D6—Hydroxyurea—hematologic cancer	0.0257	0.0385	CbGbCtD
Dolasetron—CYP2C9—Bortezomib—hematologic cancer	0.0244	0.0366	CbGbCtD
Dolasetron—CYP3A4—Bexarotene—hematologic cancer	0.0232	0.0347	CbGbCtD
Dolasetron—CYP2D6—Bortezomib—hematologic cancer	0.0223	0.0335	CbGbCtD
Dolasetron—CYP3A4—Busulfan—hematologic cancer	0.0216	0.0323	CbGbCtD
Dolasetron—CYP3A4—Lomustine—hematologic cancer	0.0216	0.0323	CbGbCtD
Dolasetron—CYP2C9—Thalidomide—hematologic cancer	0.0213	0.0319	CbGbCtD
Dolasetron—CYP2C9—Teniposide—hematologic cancer	0.0203	0.0304	CbGbCtD
Dolasetron—CYP3A4—Thiotepa—hematologic cancer	0.0192	0.0288	CbGbCtD
Dolasetron—CYP2C9—Ifosfamide—hematologic cancer	0.0187	0.0281	CbGbCtD
Dolasetron—CYP2C9—Imatinib—hematologic cancer	0.0179	0.0268	CbGbCtD
Dolasetron—CYP2D6—Imatinib—hematologic cancer	0.0164	0.0245	CbGbCtD
Dolasetron—CYP2C9—Nilotinib—hematologic cancer	0.0163	0.0244	CbGbCtD
Dolasetron—CYP3A4—Methoxsalen—hematologic cancer	0.0149	0.0224	CbGbCtD
Dolasetron—CYP2D6—Nilotinib—hematologic cancer	0.0149	0.0223	CbGbCtD
Dolasetron—CYP2D6—Vinorelbine—hematologic cancer	0.0148	0.0221	CbGbCtD
Dolasetron—CYP3A4—Bortezomib—hematologic cancer	0.0142	0.0213	CbGbCtD
Dolasetron—CYP3A4—Daunorubicin—hematologic cancer	0.0136	0.0204	CbGbCtD
Dolasetron—CYP3A4—Cytarabine—hematologic cancer	0.012	0.018	CbGbCtD
Dolasetron—CYP3A4—Teniposide—hematologic cancer	0.0118	0.0177	CbGbCtD
Dolasetron—CYP3A4—Ifosfamide—hematologic cancer	0.0109	0.0163	CbGbCtD
Dolasetron—CYP3A4—Imatinib—hematologic cancer	0.0104	0.0156	CbGbCtD
Dolasetron—CYP3A4—Ruxolitinib—hematologic cancer	0.0098	0.0147	CbGbCtD
Dolasetron—CYP3A4—Nilotinib—hematologic cancer	0.00946	0.0142	CbGbCtD
Dolasetron—CYP3A4—Vinorelbine—hematologic cancer	0.00938	0.0141	CbGbCtD
Dolasetron—CYP2C9—Cisplatin—hematologic cancer	0.00912	0.0137	CbGbCtD
Dolasetron—CYP2D6—Vinblastine—hematologic cancer	0.00909	0.0136	CbGbCtD
Dolasetron—CYP3A4—Triamcinolone—hematologic cancer	0.00858	0.0129	CbGbCtD
Dolasetron—CYP3A4—Dasatinib—hematologic cancer	0.00836	0.0125	CbGbCtD
Dolasetron—CYP3A4—Mitoxantrone—hematologic cancer	0.00826	0.0124	CbGbCtD
Dolasetron—CYP2C9—Dexamethasone—hematologic cancer	0.00736	0.011	CbGbCtD
Dolasetron—CYP3A4—Betamethasone—hematologic cancer	0.00736	0.011	CbGbCtD
Dolasetron—CYP3A4—Prednisolone—hematologic cancer	0.00726	0.0109	CbGbCtD
Dolasetron—CYP3A4—Prednisone—hematologic cancer	0.00686	0.0103	CbGbCtD
Dolasetron—CYP2D6—Dexamethasone—hematologic cancer	0.00673	0.0101	CbGbCtD
Dolasetron—CYP3A4—Irinotecan—hematologic cancer	0.0065	0.00974	CbGbCtD
Dolasetron—CYP3A4—Vinblastine—hematologic cancer	0.00578	0.00866	CbGbCtD
Dolasetron—CYP3A4—Vincristine—hematologic cancer	0.00568	0.00852	CbGbCtD
Dolasetron—CYP2D6—Doxorubicin—hematologic cancer	0.00559	0.00837	CbGbCtD
Dolasetron—CYP3A4—Etoposide—hematologic cancer	0.00521	0.0078	CbGbCtD
Dolasetron—CYP3A4—Dexamethasone—hematologic cancer	0.00428	0.00642	CbGbCtD
Dolasetron—CYP3A4—Doxorubicin—hematologic cancer	0.00355	0.00532	CbGbCtD
Dolasetron—Rash—Mitoxantrone—hematologic cancer	4.37e-05	0.000136	CcSEcCtD
Dolasetron—Rash—Irinotecan—hematologic cancer	4.37e-05	0.000136	CcSEcCtD
Dolasetron—Dermatitis—Irinotecan—hematologic cancer	4.37e-05	0.000136	CcSEcCtD
Dolasetron—Dermatitis—Mitoxantrone—hematologic cancer	4.37e-05	0.000136	CcSEcCtD
Dolasetron—Chills—Methotrexate—hematologic cancer	4.36e-05	0.000136	CcSEcCtD
Dolasetron—Headache—Mitoxantrone—hematologic cancer	4.34e-05	0.000135	CcSEcCtD
Dolasetron—Headache—Irinotecan—hematologic cancer	4.34e-05	0.000135	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.32e-05	0.000135	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.32e-05	0.000135	CcSEcCtD
Dolasetron—Myalgia—Prednisone—hematologic cancer	4.31e-05	0.000134	CcSEcCtD
Dolasetron—Arthralgia—Prednisone—hematologic cancer	4.31e-05	0.000134	CcSEcCtD
Dolasetron—Feeling abnormal—Triamcinolone—hematologic cancer	4.31e-05	0.000134	CcSEcCtD
Dolasetron—Diarrhoea—Cisplatin—hematologic cancer	4.3e-05	0.000134	CcSEcCtD
Dolasetron—Anxiety—Prednisone—hematologic cancer	4.29e-05	0.000134	CcSEcCtD
Dolasetron—Bradycardia—Doxorubicin—hematologic cancer	4.28e-05	0.000133	CcSEcCtD
Dolasetron—Paraesthesia—Betamethasone—hematologic cancer	4.26e-05	0.000133	CcSEcCtD
Dolasetron—Paraesthesia—Dexamethasone—hematologic cancer	4.26e-05	0.000133	CcSEcCtD
Dolasetron—Discomfort—Prednisone—hematologic cancer	4.26e-05	0.000133	CcSEcCtD
Dolasetron—Rash—Gemcitabine—hematologic cancer	4.26e-05	0.000133	CcSEcCtD
Dolasetron—Dermatitis—Gemcitabine—hematologic cancer	4.25e-05	0.000132	CcSEcCtD
Dolasetron—Hypersensitivity—Etoposide—hematologic cancer	4.25e-05	0.000132	CcSEcCtD
Dolasetron—Tinnitus—Epirubicin—hematologic cancer	4.24e-05	0.000132	CcSEcCtD
Dolasetron—Headache—Gemcitabine—hematologic cancer	4.23e-05	0.000132	CcSEcCtD
Dolasetron—Flushing—Epirubicin—hematologic cancer	4.22e-05	0.000131	CcSEcCtD
Dolasetron—Hypersensitivity—Prednisolone—hematologic cancer	4.19e-05	0.00013	CcSEcCtD
Dolasetron—Dyspepsia—Dexamethasone—hematologic cancer	4.18e-05	0.00013	CcSEcCtD
Dolasetron—Dyspepsia—Betamethasone—hematologic cancer	4.18e-05	0.00013	CcSEcCtD
Dolasetron—Urticaria—Triamcinolone—hematologic cancer	4.15e-05	0.000129	CcSEcCtD
Dolasetron—Oedema peripheral—Doxorubicin—hematologic cancer	4.15e-05	0.000129	CcSEcCtD
Dolasetron—Dysgeusia—Methotrexate—hematologic cancer	4.14e-05	0.000129	CcSEcCtD
Dolasetron—Asthenia—Etoposide—hematologic cancer	4.14e-05	0.000129	CcSEcCtD
Dolasetron—Body temperature increased—Triamcinolone—hematologic cancer	4.13e-05	0.000129	CcSEcCtD
Dolasetron—Anaphylactic shock—Prednisone—hematologic cancer	4.13e-05	0.000129	CcSEcCtD
Dolasetron—Oedema—Prednisone—hematologic cancer	4.13e-05	0.000129	CcSEcCtD
Dolasetron—Decreased appetite—Betamethasone—hematologic cancer	4.12e-05	0.000128	CcSEcCtD
Dolasetron—Decreased appetite—Dexamethasone—hematologic cancer	4.12e-05	0.000128	CcSEcCtD
Dolasetron—Fatigue—Betamethasone—hematologic cancer	4.09e-05	0.000127	CcSEcCtD
Dolasetron—Fatigue—Dexamethasone—hematologic cancer	4.09e-05	0.000127	CcSEcCtD
Dolasetron—Chills—Epirubicin—hematologic cancer	4.08e-05	0.000127	CcSEcCtD
Dolasetron—Pruritus—Etoposide—hematologic cancer	4.08e-05	0.000127	CcSEcCtD
Dolasetron—Shock—Prednisone—hematologic cancer	4.06e-05	0.000127	CcSEcCtD
Dolasetron—Arrhythmia—Epirubicin—hematologic cancer	4.06e-05	0.000127	CcSEcCtD
Dolasetron—Pain—Betamethasone—hematologic cancer	4.06e-05	0.000126	CcSEcCtD
Dolasetron—Pain—Dexamethasone—hematologic cancer	4.06e-05	0.000126	CcSEcCtD
Dolasetron—Visual impairment—Doxorubicin—hematologic cancer	4.06e-05	0.000126	CcSEcCtD
Dolasetron—Tachycardia—Prednisone—hematologic cancer	4.03e-05	0.000126	CcSEcCtD
Dolasetron—Hyperhidrosis—Prednisone—hematologic cancer	3.99e-05	0.000124	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	3.98e-05	0.00346	CbGpPWpGaD
Dolasetron—Rash—Cisplatin—hematologic cancer	3.97e-05	0.000124	CcSEcCtD
Dolasetron—Dermatitis—Cisplatin—hematologic cancer	3.96e-05	0.000123	CcSEcCtD
Dolasetron—Diarrhoea—Etoposide—hematologic cancer	3.94e-05	0.000123	CcSEcCtD
Dolasetron—Anorexia—Prednisone—hematologic cancer	3.94e-05	0.000123	CcSEcCtD
Dolasetron—Ill-defined disorder—Methotrexate—hematologic cancer	3.93e-05	0.000122	CcSEcCtD
Dolasetron—Tinnitus—Doxorubicin—hematologic cancer	3.92e-05	0.000122	CcSEcCtD
Dolasetron—Anaemia—Methotrexate—hematologic cancer	3.91e-05	0.000122	CcSEcCtD
Dolasetron—Feeling abnormal—Dexamethasone—hematologic cancer	3.91e-05	0.000122	CcSEcCtD
Dolasetron—Feeling abnormal—Betamethasone—hematologic cancer	3.91e-05	0.000122	CcSEcCtD
Dolasetron—Flushing—Doxorubicin—hematologic cancer	3.91e-05	0.000122	CcSEcCtD
Dolasetron—Flatulence—Epirubicin—hematologic cancer	3.9e-05	0.000121	CcSEcCtD
Dolasetron—Gastrointestinal pain—Betamethasone—hematologic cancer	3.88e-05	0.000121	CcSEcCtD
Dolasetron—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.88e-05	0.000121	CcSEcCtD
Dolasetron—Dysgeusia—Epirubicin—hematologic cancer	3.88e-05	0.000121	CcSEcCtD
Dolasetron—Hypersensitivity—Triamcinolone—hematologic cancer	3.85e-05	0.00012	CcSEcCtD
Dolasetron—Malaise—Methotrexate—hematologic cancer	3.81e-05	0.000119	CcSEcCtD
Dolasetron—Dizziness—Etoposide—hematologic cancer	3.81e-05	0.000119	CcSEcCtD
Dolasetron—Vertigo—Methotrexate—hematologic cancer	3.8e-05	0.000118	CcSEcCtD
Dolasetron—Chills—Doxorubicin—hematologic cancer	3.78e-05	0.000118	CcSEcCtD
Dolasetron—Urticaria—Betamethasone—hematologic cancer	3.77e-05	0.000117	CcSEcCtD
Dolasetron—Urticaria—Dexamethasone—hematologic cancer	3.77e-05	0.000117	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.76e-05	0.000117	CcSEcCtD
Dolasetron—Dizziness—Prednisolone—hematologic cancer	3.76e-05	0.000117	CcSEcCtD
Dolasetron—Arrhythmia—Doxorubicin—hematologic cancer	3.76e-05	0.000117	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—NUP98—hematologic cancer	3.75e-05	0.00327	CbGpPWpGaD
Dolasetron—Asthenia—Triamcinolone—hematologic cancer	3.75e-05	0.000117	CcSEcCtD
Dolasetron—Abdominal pain—Betamethasone—hematologic cancer	3.75e-05	0.000117	CcSEcCtD
Dolasetron—Abdominal pain—Dexamethasone—hematologic cancer	3.75e-05	0.000117	CcSEcCtD
Dolasetron—Body temperature increased—Dexamethasone—hematologic cancer	3.75e-05	0.000117	CcSEcCtD
Dolasetron—Body temperature increased—Betamethasone—hematologic cancer	3.75e-05	0.000117	CcSEcCtD
Dolasetron—Paraesthesia—Prednisone—hematologic cancer	3.71e-05	0.000116	CcSEcCtD
Dolasetron—Pruritus—Triamcinolone—hematologic cancer	3.7e-05	0.000115	CcSEcCtD
Dolasetron—Cough—Methotrexate—hematologic cancer	3.69e-05	0.000115	CcSEcCtD
Dolasetron—Ill-defined disorder—Epirubicin—hematologic cancer	3.67e-05	0.000114	CcSEcCtD
Dolasetron—Convulsion—Methotrexate—hematologic cancer	3.67e-05	0.000114	CcSEcCtD
Dolasetron—Anaemia—Epirubicin—hematologic cancer	3.66e-05	0.000114	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ADCY7—hematologic cancer	3.64e-05	0.00317	CbGpPWpGaD
Dolasetron—Agitation—Epirubicin—hematologic cancer	3.64e-05	0.000113	CcSEcCtD
Dolasetron—Dyspepsia—Prednisone—hematologic cancer	3.64e-05	0.000113	CcSEcCtD
Dolasetron—Rash—Etoposide—hematologic cancer	3.63e-05	0.000113	CcSEcCtD
Dolasetron—Dermatitis—Etoposide—hematologic cancer	3.63e-05	0.000113	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—NUP214—hematologic cancer	3.62e-05	0.00315	CbGpPWpGaD
Dolasetron—Headache—Etoposide—hematologic cancer	3.61e-05	0.000112	CcSEcCtD
Dolasetron—Flatulence—Doxorubicin—hematologic cancer	3.61e-05	0.000112	CcSEcCtD
Dolasetron—Chest pain—Methotrexate—hematologic cancer	3.6e-05	0.000112	CcSEcCtD
Dolasetron—Arthralgia—Methotrexate—hematologic cancer	3.6e-05	0.000112	CcSEcCtD
Dolasetron—Myalgia—Methotrexate—hematologic cancer	3.6e-05	0.000112	CcSEcCtD
Dolasetron—Decreased appetite—Prednisone—hematologic cancer	3.59e-05	0.000112	CcSEcCtD
Dolasetron—Dysgeusia—Doxorubicin—hematologic cancer	3.59e-05	0.000112	CcSEcCtD
Dolasetron—Rash—Prednisolone—hematologic cancer	3.58e-05	0.000112	CcSEcCtD
Dolasetron—Dermatitis—Prednisolone—hematologic cancer	3.58e-05	0.000112	CcSEcCtD
Dolasetron—Malaise—Epirubicin—hematologic cancer	3.57e-05	0.000111	CcSEcCtD
Dolasetron—Fatigue—Prednisone—hematologic cancer	3.56e-05	0.000111	CcSEcCtD
Dolasetron—Headache—Prednisolone—hematologic cancer	3.56e-05	0.000111	CcSEcCtD
Dolasetron—Discomfort—Methotrexate—hematologic cancer	3.56e-05	0.000111	CcSEcCtD
Dolasetron—Vertigo—Epirubicin—hematologic cancer	3.56e-05	0.000111	CcSEcCtD
Dolasetron—Syncope—Epirubicin—hematologic cancer	3.55e-05	0.000111	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ABCG2—hematologic cancer	3.54e-05	0.00308	CbGpPWpGaD
Dolasetron—Constipation—Prednisone—hematologic cancer	3.53e-05	0.00011	CcSEcCtD
Dolasetron—Palpitations—Epirubicin—hematologic cancer	3.5e-05	0.000109	CcSEcCtD
Dolasetron—Confusional state—Methotrexate—hematologic cancer	3.48e-05	0.000108	CcSEcCtD
Dolasetron—Loss of consciousness—Epirubicin—hematologic cancer	3.48e-05	0.000108	CcSEcCtD
Dolasetron—Dizziness—Triamcinolone—hematologic cancer	3.46e-05	0.000108	CcSEcCtD
Dolasetron—Cough—Epirubicin—hematologic cancer	3.45e-05	0.000108	CcSEcCtD
Dolasetron—Anaphylactic shock—Methotrexate—hematologic cancer	3.45e-05	0.000108	CcSEcCtD
Dolasetron—Convulsion—Epirubicin—hematologic cancer	3.43e-05	0.000107	CcSEcCtD
Dolasetron—Hypertension—Epirubicin—hematologic cancer	3.42e-05	0.000106	CcSEcCtD
Dolasetron—Feeling abnormal—Prednisone—hematologic cancer	3.4e-05	0.000106	CcSEcCtD
Dolasetron—Asthenia—Betamethasone—hematologic cancer	3.4e-05	0.000106	CcSEcCtD
Dolasetron—Asthenia—Dexamethasone—hematologic cancer	3.4e-05	0.000106	CcSEcCtD
Dolasetron—Ill-defined disorder—Doxorubicin—hematologic cancer	3.4e-05	0.000106	CcSEcCtD
Dolasetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	3.39e-05	0.00295	CbGpPWpGaD
Dolasetron—Anaemia—Doxorubicin—hematologic cancer	3.39e-05	0.000105	CcSEcCtD
Dolasetron—Thrombocytopenia—Methotrexate—hematologic cancer	3.38e-05	0.000105	CcSEcCtD
Dolasetron—Gastrointestinal pain—Prednisone—hematologic cancer	3.38e-05	0.000105	CcSEcCtD
Dolasetron—Chest pain—Epirubicin—hematologic cancer	3.37e-05	0.000105	CcSEcCtD
Dolasetron—Arthralgia—Epirubicin—hematologic cancer	3.37e-05	0.000105	CcSEcCtD
Dolasetron—Myalgia—Epirubicin—hematologic cancer	3.37e-05	0.000105	CcSEcCtD
Dolasetron—Agitation—Doxorubicin—hematologic cancer	3.37e-05	0.000105	CcSEcCtD
Dolasetron—Anxiety—Epirubicin—hematologic cancer	3.36e-05	0.000105	CcSEcCtD
Dolasetron—Pruritus—Betamethasone—hematologic cancer	3.36e-05	0.000105	CcSEcCtD
Dolasetron—Pruritus—Dexamethasone—hematologic cancer	3.36e-05	0.000105	CcSEcCtD
Dolasetron—Hyperhidrosis—Methotrexate—hematologic cancer	3.34e-05	0.000104	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—IL1B—hematologic cancer	3.34e-05	0.0029	CbGpPWpGaD
Dolasetron—Discomfort—Epirubicin—hematologic cancer	3.33e-05	0.000104	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—CASP3—hematologic cancer	3.33e-05	0.0029	CbGpPWpGaD
Dolasetron—Malaise—Doxorubicin—hematologic cancer	3.3e-05	0.000103	CcSEcCtD
Dolasetron—Rash—Triamcinolone—hematologic cancer	3.3e-05	0.000103	CcSEcCtD
Dolasetron—Dry mouth—Epirubicin—hematologic cancer	3.3e-05	0.000103	CcSEcCtD
Dolasetron—Dermatitis—Triamcinolone—hematologic cancer	3.29e-05	0.000103	CcSEcCtD
Dolasetron—Vertigo—Doxorubicin—hematologic cancer	3.29e-05	0.000102	CcSEcCtD
Dolasetron—Anorexia—Methotrexate—hematologic cancer	3.29e-05	0.000102	CcSEcCtD
Dolasetron—Syncope—Doxorubicin—hematologic cancer	3.29e-05	0.000102	CcSEcCtD
Dolasetron—Urticaria—Prednisone—hematologic cancer	3.28e-05	0.000102	CcSEcCtD
Dolasetron—Headache—Triamcinolone—hematologic cancer	3.28e-05	0.000102	CcSEcCtD
Dolasetron—Abdominal pain—Prednisone—hematologic cancer	3.27e-05	0.000102	CcSEcCtD
Dolasetron—Body temperature increased—Prednisone—hematologic cancer	3.27e-05	0.000102	CcSEcCtD
Dolasetron—Confusional state—Epirubicin—hematologic cancer	3.26e-05	0.000101	CcSEcCtD
Dolasetron—Diarrhoea—Betamethasone—hematologic cancer	3.25e-05	0.000101	CcSEcCtD
Dolasetron—Diarrhoea—Dexamethasone—hematologic cancer	3.25e-05	0.000101	CcSEcCtD
Dolasetron—Palpitations—Doxorubicin—hematologic cancer	3.24e-05	0.000101	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—JUN—hematologic cancer	3.23e-05	0.00281	CbGpPWpGaD
Dolasetron—Anaphylactic shock—Epirubicin—hematologic cancer	3.23e-05	0.000101	CcSEcCtD
Dolasetron—Oedema—Epirubicin—hematologic cancer	3.23e-05	0.000101	CcSEcCtD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—hematologic cancer	3.23e-05	0.00281	CbGpPWpGaD
Dolasetron—Hypotension—Methotrexate—hematologic cancer	3.23e-05	0.0001	CcSEcCtD
Dolasetron—Loss of consciousness—Doxorubicin—hematologic cancer	3.22e-05	0.0001	CcSEcCtD
Dolasetron—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	3.2e-05	0.00279	CbGpPWpGaD
Dolasetron—Cough—Doxorubicin—hematologic cancer	3.2e-05	9.95e-05	CcSEcCtD
Dolasetron—Shock—Epirubicin—hematologic cancer	3.18e-05	9.9e-05	CcSEcCtD
Dolasetron—Convulsion—Doxorubicin—hematologic cancer	3.17e-05	9.88e-05	CcSEcCtD
Dolasetron—Thrombocytopenia—Epirubicin—hematologic cancer	3.16e-05	9.85e-05	CcSEcCtD
Dolasetron—Hypertension—Doxorubicin—hematologic cancer	3.16e-05	9.85e-05	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—TFRC—hematologic cancer	3.16e-05	0.00275	CbGpPWpGaD
Dolasetron—Tachycardia—Epirubicin—hematologic cancer	3.15e-05	9.82e-05	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.15e-05	9.8e-05	CcSEcCtD
Dolasetron—Dizziness—Dexamethasone—hematologic cancer	3.14e-05	9.77e-05	CcSEcCtD
Dolasetron—Dizziness—Betamethasone—hematologic cancer	3.14e-05	9.77e-05	CcSEcCtD
Dolasetron—Hyperhidrosis—Epirubicin—hematologic cancer	3.12e-05	9.73e-05	CcSEcCtD
Dolasetron—Chest pain—Doxorubicin—hematologic cancer	3.12e-05	9.71e-05	CcSEcCtD
Dolasetron—Myalgia—Doxorubicin—hematologic cancer	3.12e-05	9.71e-05	CcSEcCtD
Dolasetron—Arthralgia—Doxorubicin—hematologic cancer	3.12e-05	9.71e-05	CcSEcCtD
Dolasetron—Anxiety—Doxorubicin—hematologic cancer	3.11e-05	9.68e-05	CcSEcCtD
Dolasetron—Paraesthesia—Methotrexate—hematologic cancer	3.1e-05	9.66e-05	CcSEcCtD
Dolasetron—Discomfort—Doxorubicin—hematologic cancer	3.08e-05	9.6e-05	CcSEcCtD
Dolasetron—Anorexia—Epirubicin—hematologic cancer	3.08e-05	9.59e-05	CcSEcCtD
Dolasetron—Dyspnoea—Methotrexate—hematologic cancer	3.08e-05	9.59e-05	CcSEcCtD
Dolasetron—Somnolence—Methotrexate—hematologic cancer	3.07e-05	9.56e-05	CcSEcCtD
Dolasetron—Dry mouth—Doxorubicin—hematologic cancer	3.05e-05	9.5e-05	CcSEcCtD
Dolasetron—Hypersensitivity—Prednisone—hematologic cancer	3.04e-05	9.48e-05	CcSEcCtD
Dolasetron—Dyspepsia—Methotrexate—hematologic cancer	3.04e-05	9.46e-05	CcSEcCtD
Dolasetron—Hypotension—Epirubicin—hematologic cancer	3.02e-05	9.4e-05	CcSEcCtD
Dolasetron—Confusional state—Doxorubicin—hematologic cancer	3.01e-05	9.39e-05	CcSEcCtD
Dolasetron—Decreased appetite—Methotrexate—hematologic cancer	3e-05	9.35e-05	CcSEcCtD
Dolasetron—Rash—Dexamethasone—hematologic cancer	2.99e-05	9.31e-05	CcSEcCtD
Dolasetron—Rash—Betamethasone—hematologic cancer	2.99e-05	9.31e-05	CcSEcCtD
Dolasetron—Oedema—Doxorubicin—hematologic cancer	2.99e-05	9.31e-05	CcSEcCtD
Dolasetron—Anaphylactic shock—Doxorubicin—hematologic cancer	2.99e-05	9.31e-05	CcSEcCtD
Dolasetron—Dermatitis—Betamethasone—hematologic cancer	2.99e-05	9.31e-05	CcSEcCtD
Dolasetron—Dermatitis—Dexamethasone—hematologic cancer	2.99e-05	9.31e-05	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—EP300—hematologic cancer	2.98e-05	0.00259	CbGpPWpGaD
Dolasetron—Fatigue—Methotrexate—hematologic cancer	2.98e-05	9.27e-05	CcSEcCtD
Dolasetron—Headache—Dexamethasone—hematologic cancer	2.97e-05	9.26e-05	CcSEcCtD
Dolasetron—Headache—Betamethasone—hematologic cancer	2.97e-05	9.26e-05	CcSEcCtD
Dolasetron—Asthenia—Prednisone—hematologic cancer	2.96e-05	9.23e-05	CcSEcCtD
Dolasetron—Pain—Methotrexate—hematologic cancer	2.95e-05	9.19e-05	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.94e-05	9.17e-05	CcSEcCtD
Dolasetron—Shock—Doxorubicin—hematologic cancer	2.94e-05	9.16e-05	CcSEcCtD
Dolasetron—Thrombocytopenia—Doxorubicin—hematologic cancer	2.93e-05	9.12e-05	CcSEcCtD
Dolasetron—Pruritus—Prednisone—hematologic cancer	2.92e-05	9.1e-05	CcSEcCtD
Dolasetron—Tachycardia—Doxorubicin—hematologic cancer	2.92e-05	9.09e-05	CcSEcCtD
Dolasetron—Paraesthesia—Epirubicin—hematologic cancer	2.9e-05	9.04e-05	CcSEcCtD
Dolasetron—Hyperhidrosis—Doxorubicin—hematologic cancer	2.89e-05	9e-05	CcSEcCtD
Dolasetron—Dyspnoea—Epirubicin—hematologic cancer	2.88e-05	8.97e-05	CcSEcCtD
Dolasetron—Somnolence—Epirubicin—hematologic cancer	2.87e-05	8.95e-05	CcSEcCtD
Dolasetron—Anorexia—Doxorubicin—hematologic cancer	2.85e-05	8.87e-05	CcSEcCtD
Dolasetron—Feeling abnormal—Methotrexate—hematologic cancer	2.85e-05	8.86e-05	CcSEcCtD
Dolasetron—Dyspepsia—Epirubicin—hematologic cancer	2.84e-05	8.86e-05	CcSEcCtD
Dolasetron—Diarrhoea—Prednisone—hematologic cancer	2.83e-05	8.8e-05	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	2.82e-05	0.00246	CbGpPWpGaD
Dolasetron—Gastrointestinal pain—Methotrexate—hematologic cancer	2.82e-05	8.79e-05	CcSEcCtD
Dolasetron—Decreased appetite—Epirubicin—hematologic cancer	2.81e-05	8.75e-05	CcSEcCtD
Dolasetron—Hypotension—Doxorubicin—hematologic cancer	2.79e-05	8.7e-05	CcSEcCtD
Dolasetron—Fatigue—Epirubicin—hematologic cancer	2.79e-05	8.68e-05	CcSEcCtD
Dolasetron—Constipation—Epirubicin—hematologic cancer	2.76e-05	8.6e-05	CcSEcCtD
Dolasetron—Pain—Epirubicin—hematologic cancer	2.76e-05	8.6e-05	CcSEcCtD
Dolasetron—Urticaria—Methotrexate—hematologic cancer	2.74e-05	8.54e-05	CcSEcCtD
Dolasetron—Dizziness—Prednisone—hematologic cancer	2.73e-05	8.51e-05	CcSEcCtD
Dolasetron—Abdominal pain—Methotrexate—hematologic cancer	2.73e-05	8.5e-05	CcSEcCtD
Dolasetron—Body temperature increased—Methotrexate—hematologic cancer	2.73e-05	8.5e-05	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.72e-05	8.48e-05	CcSEcCtD
Dolasetron—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	2.69e-05	0.00234	CbGpPWpGaD
Dolasetron—Paraesthesia—Doxorubicin—hematologic cancer	2.68e-05	8.36e-05	CcSEcCtD
Dolasetron—Dyspnoea—Doxorubicin—hematologic cancer	2.67e-05	8.3e-05	CcSEcCtD
Dolasetron—Feeling abnormal—Epirubicin—hematologic cancer	2.66e-05	8.29e-05	CcSEcCtD
Dolasetron—Somnolence—Doxorubicin—hematologic cancer	2.66e-05	8.28e-05	CcSEcCtD
Dolasetron—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	2.65e-05	0.00231	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTO1—hematologic cancer	2.65e-05	0.00231	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—CYCS—hematologic cancer	2.65e-05	0.00231	CbGpPWpGaD
Dolasetron—Gastrointestinal pain—Epirubicin—hematologic cancer	2.64e-05	8.23e-05	CcSEcCtD
Dolasetron—Dyspepsia—Doxorubicin—hematologic cancer	2.63e-05	8.2e-05	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—GSTO1—hematologic cancer	2.63e-05	0.00229	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTO1—hematologic cancer	2.62e-05	0.00228	CbGpPWpGaD
Dolasetron—Rash—Prednisone—hematologic cancer	2.6e-05	8.11e-05	CcSEcCtD
Dolasetron—Dermatitis—Prednisone—hematologic cancer	2.6e-05	8.1e-05	CcSEcCtD
Dolasetron—Decreased appetite—Doxorubicin—hematologic cancer	2.6e-05	8.09e-05	CcSEcCtD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTO1—hematologic cancer	2.59e-05	0.00226	CbGpPWpGaD
Dolasetron—Headache—Prednisone—hematologic cancer	2.59e-05	8.06e-05	CcSEcCtD
Dolasetron—Fatigue—Doxorubicin—hematologic cancer	2.58e-05	8.03e-05	CcSEcCtD
Dolasetron—Urticaria—Epirubicin—hematologic cancer	2.57e-05	7.99e-05	CcSEcCtD
Dolasetron—Constipation—Doxorubicin—hematologic cancer	2.56e-05	7.96e-05	CcSEcCtD
Dolasetron—Pain—Doxorubicin—hematologic cancer	2.56e-05	7.96e-05	CcSEcCtD
Dolasetron—Abdominal pain—Epirubicin—hematologic cancer	2.55e-05	7.95e-05	CcSEcCtD
Dolasetron—Body temperature increased—Epirubicin—hematologic cancer	2.55e-05	7.95e-05	CcSEcCtD
Dolasetron—Hypersensitivity—Methotrexate—hematologic cancer	2.54e-05	7.92e-05	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—UGT1A1—hematologic cancer	2.49e-05	0.00217	CbGpPWpGaD
Dolasetron—Asthenia—Methotrexate—hematologic cancer	2.48e-05	7.71e-05	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—UGT1A1—hematologic cancer	2.47e-05	0.00215	CbGpPWpGaD
Dolasetron—Feeling abnormal—Doxorubicin—hematologic cancer	2.46e-05	7.67e-05	CcSEcCtD
Dolasetron—CYP2D6—Metapathway biotransformation—UGT1A1—hematologic cancer	2.46e-05	0.00214	CbGpPWpGaD
Dolasetron—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.44e-05	7.61e-05	CcSEcCtD
Dolasetron—Pruritus—Methotrexate—hematologic cancer	2.44e-05	7.61e-05	CcSEcCtD
Dolasetron—CYP2C9—Metapathway biotransformation—UGT1A1—hematologic cancer	2.44e-05	0.00212	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PHYH—hematologic cancer	2.43e-05	0.00212	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—TNF—hematologic cancer	2.42e-05	0.00211	CbGpPWpGaD
Dolasetron—Hypersensitivity—Epirubicin—hematologic cancer	2.38e-05	7.41e-05	CcSEcCtD
Dolasetron—Urticaria—Doxorubicin—hematologic cancer	2.38e-05	7.4e-05	CcSEcCtD
Dolasetron—Abdominal pain—Doxorubicin—hematologic cancer	2.36e-05	7.36e-05	CcSEcCtD
Dolasetron—Body temperature increased—Doxorubicin—hematologic cancer	2.36e-05	7.36e-05	CcSEcCtD
Dolasetron—Diarrhoea—Methotrexate—hematologic cancer	2.36e-05	7.36e-05	CcSEcCtD
Dolasetron—Asthenia—Epirubicin—hematologic cancer	2.32e-05	7.22e-05	CcSEcCtD
Dolasetron—Pruritus—Epirubicin—hematologic cancer	2.29e-05	7.12e-05	CcSEcCtD
Dolasetron—Dizziness—Methotrexate—hematologic cancer	2.28e-05	7.11e-05	CcSEcCtD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—SMPD3—hematologic cancer	2.22e-05	0.00193	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ABCB1—hematologic cancer	2.21e-05	0.00192	CbGpPWpGaD
Dolasetron—Diarrhoea—Epirubicin—hematologic cancer	2.21e-05	6.88e-05	CcSEcCtD
Dolasetron—Hypersensitivity—Doxorubicin—hematologic cancer	2.2e-05	6.86e-05	CcSEcCtD
Dolasetron—Rash—Methotrexate—hematologic cancer	2.18e-05	6.78e-05	CcSEcCtD
Dolasetron—Dermatitis—Methotrexate—hematologic cancer	2.17e-05	6.77e-05	CcSEcCtD
Dolasetron—Headache—Methotrexate—hematologic cancer	2.16e-05	6.74e-05	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—MTR—hematologic cancer	2.16e-05	0.00188	CbGpPWpGaD
Dolasetron—Asthenia—Doxorubicin—hematologic cancer	2.14e-05	6.68e-05	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—MTR—hematologic cancer	2.14e-05	0.00186	CbGpPWpGaD
Dolasetron—Dizziness—Epirubicin—hematologic cancer	2.14e-05	6.65e-05	CcSEcCtD
Dolasetron—Pruritus—Doxorubicin—hematologic cancer	2.12e-05	6.59e-05	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—GSTT1—hematologic cancer	2.06e-05	0.00179	CbGpPWpGaD
Dolasetron—Diarrhoea—Doxorubicin—hematologic cancer	2.05e-05	6.37e-05	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—GSTT1—hematologic cancer	2.04e-05	0.00177	CbGpPWpGaD
Dolasetron—Rash—Epirubicin—hematologic cancer	2.04e-05	6.34e-05	CcSEcCtD
Dolasetron—Dermatitis—Epirubicin—hematologic cancer	2.04e-05	6.34e-05	CcSEcCtD
Dolasetron—Headache—Epirubicin—hematologic cancer	2.02e-05	6.3e-05	CcSEcCtD
Dolasetron—Dizziness—Doxorubicin—hematologic cancer	1.98e-05	6.16e-05	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—IL6—hematologic cancer	1.95e-05	0.0017	CbGpPWpGaD
Dolasetron—Rash—Doxorubicin—hematologic cancer	1.89e-05	5.87e-05	CcSEcCtD
Dolasetron—Dermatitis—Doxorubicin—hematologic cancer	1.88e-05	5.87e-05	CcSEcCtD
Dolasetron—Headache—Doxorubicin—hematologic cancer	1.87e-05	5.83e-05	CcSEcCtD
Dolasetron—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	1.73e-05	0.00151	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	1.71e-05	0.00149	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	1.63e-05	0.00142	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	1.61e-05	0.0014	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	1.57e-05	0.00136	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.48e-05	0.00129	CbGpPWpGaD
Dolasetron—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	1.44e-05	0.00125	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTP1—hematologic cancer	1.43e-05	0.00124	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—MTR—hematologic cancer	1.41e-05	0.00123	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTP1—hematologic cancer	1.41e-05	0.00123	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTP1—hematologic cancer	1.41e-05	0.00122	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTP1—hematologic cancer	1.39e-05	0.00121	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ALB—hematologic cancer	1.38e-05	0.0012	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	1.34e-05	0.00117	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTM1—hematologic cancer	1.31e-05	0.00114	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTM1—hematologic cancer	1.3e-05	0.00113	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTM1—hematologic cancer	1.29e-05	0.00112	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTM1—hematologic cancer	1.28e-05	0.00111	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	1.28e-05	0.00111	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	1.12e-05	0.000971	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GMPS—hematologic cancer	1.09e-05	0.00095	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PHYH—hematologic cancer	1.09e-05	0.00095	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—FTCD—hematologic cancer	1.09e-05	0.00095	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—FTCD—hematologic cancer	1.08e-05	0.000942	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PHYH—hematologic cancer	1.08e-05	0.000942	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GMPS—hematologic cancer	1.08e-05	0.000942	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	1.07e-05	0.000933	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	1.02e-05	0.000888	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	1.01e-05	0.000878	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SMPD3—hematologic cancer	9.99e-06	0.000869	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SMPD3—hematologic cancer	9.9e-06	0.000862	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	9.88e-06	0.00086	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	9.32e-06	0.000811	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	9.23e-06	0.000803	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	9.19e-06	0.0008	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	9e-06	0.000783	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ASNS—hematologic cancer	8.73e-06	0.00076	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—B3GAT1—hematologic cancer	8.73e-06	0.00076	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—DCK—hematologic cancer	8.73e-06	0.00076	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—B3GAT1—hematologic cancer	8.66e-06	0.000753	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ASNS—hematologic cancer	8.66e-06	0.000753	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—DCK—hematologic cancer	8.66e-06	0.000753	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	8.56e-06	0.000745	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	8.46e-06	0.000736	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	8.45e-06	0.000735	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HDC—hematologic cancer	8.28e-06	0.00072	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HDC—hematologic cancer	8.21e-06	0.000714	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	7.65e-06	0.000666	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CDA—hematologic cancer	7.57e-06	0.000659	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CDA—hematologic cancer	7.51e-06	0.000653	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PC—hematologic cancer	7.29e-06	0.000634	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PC—hematologic cancer	7.22e-06	0.000629	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GMPS—hematologic cancer	7.14e-06	0.000621	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—FTCD—hematologic cancer	7.14e-06	0.000621	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PHYH—hematologic cancer	7.14e-06	0.000621	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GBA—hematologic cancer	7.04e-06	0.000612	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SLC35B2—hematologic cancer	7.04e-06	0.000612	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SLC35B2—hematologic cancer	6.98e-06	0.000607	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GBA—hematologic cancer	6.98e-06	0.000607	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SMPD3—hematologic cancer	6.53e-06	0.000568	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—MTAP—hematologic cancer	6.44e-06	0.00056	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—MTAP—hematologic cancer	6.38e-06	0.000555	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—FHL2—hematologic cancer	5.74e-06	0.000499	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—B3GAT1—hematologic cancer	5.71e-06	0.000497	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—DCK—hematologic cancer	5.71e-06	0.000497	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ASNS—hematologic cancer	5.71e-06	0.000497	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—FHL2—hematologic cancer	5.69e-06	0.000495	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—AGRN—hematologic cancer	5.63e-06	0.00049	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—AGRN—hematologic cancer	5.58e-06	0.000485	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HDC—hematologic cancer	5.41e-06	0.000471	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HMMR—hematologic cancer	5.33e-06	0.000464	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—IDH2—hematologic cancer	5.33e-06	0.000464	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HMMR—hematologic cancer	5.29e-06	0.00046	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—IDH2—hematologic cancer	5.29e-06	0.00046	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ARNTL—hematologic cancer	5.01e-06	0.000436	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	4.99e-06	0.000434	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ARNTL—hematologic cancer	4.97e-06	0.000433	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CDA—hematologic cancer	4.95e-06	0.000431	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CA9—hematologic cancer	4.88e-06	0.000424	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ACP5—hematologic cancer	4.88e-06	0.000424	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ACP5—hematologic cancer	4.84e-06	0.000421	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CA9—hematologic cancer	4.84e-06	0.000421	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NCOR2—hematologic cancer	4.81e-06	0.000419	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NCOR2—hematologic cancer	4.77e-06	0.000415	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PC—hematologic cancer	4.76e-06	0.000415	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GBA—hematologic cancer	4.6e-06	0.0004	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SLC35B2—hematologic cancer	4.6e-06	0.0004	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—IDH1—hematologic cancer	4.59e-06	0.000399	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—IDH1—hematologic cancer	4.55e-06	0.000396	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTO1—hematologic cancer	4.54e-06	0.000395	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TXN—hematologic cancer	4.54e-06	0.000395	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ABCC3—hematologic cancer	4.54e-06	0.000395	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTO1—hematologic cancer	4.5e-06	0.000391	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TXN—hematologic cancer	4.5e-06	0.000391	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ABCC3—hematologic cancer	4.5e-06	0.000391	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SPHK1—hematologic cancer	4.44e-06	0.000386	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SPHK1—hematologic cancer	4.4e-06	0.000383	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—UGT1A1—hematologic cancer	4.26e-06	0.000371	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—UGT1A1—hematologic cancer	4.23e-06	0.000368	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MTAP—hematologic cancer	4.21e-06	0.000366	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SLC22A1—hematologic cancer	4.15e-06	0.000361	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CRABP1—hematologic cancer	4.15e-06	0.000361	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CRABP1—hematologic cancer	4.11e-06	0.000358	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SLC22A1—hematologic cancer	4.11e-06	0.000358	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALOX5—hematologic cancer	4.04e-06	0.000352	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALOX5—hematologic cancer	4.01e-06	0.000349	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NUP98—hematologic cancer	3.91e-06	0.000341	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NUP98—hematologic cancer	3.88e-06	0.000338	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ADCY7—hematologic cancer	3.8e-06	0.000331	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NCOA3—hematologic cancer	3.8e-06	0.000331	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NUP214—hematologic cancer	3.77e-06	0.000328	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ADCY7—hematologic cancer	3.77e-06	0.000328	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NCOA3—hematologic cancer	3.77e-06	0.000328	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—FHL2—hematologic cancer	3.75e-06	0.000326	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NUP214—hematologic cancer	3.74e-06	0.000326	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.7e-06	0.000322	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—MTR—hematologic cancer	3.7e-06	0.000322	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ABCG2—hematologic cancer	3.7e-06	0.000322	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—AGRN—hematologic cancer	3.68e-06	0.00032	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ABCG2—hematologic cancer	3.67e-06	0.000319	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—MTR—hematologic cancer	3.67e-06	0.000319	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ENO2—hematologic cancer	3.63e-06	0.000315	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ENO2—hematologic cancer	3.59e-06	0.000313	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTT1—hematologic cancer	3.52e-06	0.000306	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—IDH2—hematologic cancer	3.49e-06	0.000303	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HMMR—hematologic cancer	3.49e-06	0.000303	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTT1—hematologic cancer	3.49e-06	0.000303	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—SDC1—hematologic cancer	3.44e-06	0.000299	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.43e-06	0.000299	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—SDC1—hematologic cancer	3.41e-06	0.000296	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.28e-06	0.000285	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.25e-06	0.000283	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.21e-06	0.00028	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ACP5—hematologic cancer	3.19e-06	0.000278	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CA9—hematologic cancer	3.19e-06	0.000278	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NCOR2—hematologic cancer	3.15e-06	0.000274	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.07e-06	0.000267	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—IDH1—hematologic cancer	3e-06	0.000261	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ABCC3—hematologic cancer	2.97e-06	0.000258	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TXN—hematologic cancer	2.97e-06	0.000258	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTO1—hematologic cancer	2.97e-06	0.000258	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CD44—hematologic cancer	2.92e-06	0.000254	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NQO1—hematologic cancer	2.92e-06	0.000254	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SPHK1—hematologic cancer	2.9e-06	0.000252	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CD44—hematologic cancer	2.9e-06	0.000252	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NQO1—hematologic cancer	2.9e-06	0.000252	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.84e-06	0.000247	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.79e-06	0.000243	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYCS—hematologic cancer	2.77e-06	0.000241	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	2.75e-06	0.000239	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYCS—hematologic cancer	2.74e-06	0.000239	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	2.72e-06	0.000237	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.71e-06	0.000236	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.71e-06	0.000236	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.64e-06	0.00023	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NUP98—hematologic cancer	2.56e-06	0.000223	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.48e-06	0.000216	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.48e-06	0.000216	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NUP214—hematologic cancer	2.47e-06	0.000215	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.45e-06	0.000213	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.44e-06	0.000212	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MTR—hematologic cancer	2.42e-06	0.00021	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.42e-06	0.00021	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.42e-06	0.00021	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ENO2—hematologic cancer	2.37e-06	0.000206	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.34e-06	0.000203	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.31e-06	0.000201	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.3e-06	0.0002	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.29e-06	0.000199	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—SDC1—hematologic cancer	2.25e-06	0.000196	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.24e-06	0.000195	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.24e-06	0.000195	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.22e-06	0.000193	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.22e-06	0.000193	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.98e-06	0.000172	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.96e-06	0.000171	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CD44—hematologic cancer	1.91e-06	0.000166	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NQO1—hematologic cancer	1.91e-06	0.000166	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYCS—hematologic cancer	1.81e-06	0.000157	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.8e-06	0.000156	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.73e-06	0.00015	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.66e-06	0.000145	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.65e-06	0.000143	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.59e-06	0.000139	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.54e-06	0.000134	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.53e-06	0.000133	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.51e-06	0.000131	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.46e-06	0.000127	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.46e-06	0.000127	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.46e-06	0.000127	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.45e-06	0.000126	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALB—hematologic cancer	1.44e-06	0.000126	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALB—hematologic cancer	1.43e-06	0.000125	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.38e-06	0.00012	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.37e-06	0.000119	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.29e-06	0.000113	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.27e-06	0.000111	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.26e-06	0.00011	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PTEN—hematologic cancer	1.1e-06	9.58e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PTEN—hematologic cancer	1.09e-06	9.5e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.09e-06	9.46e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—EP300—hematologic cancer	1.05e-06	9.14e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—EP300—hematologic cancer	1.04e-06	9.06e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.01e-06	8.77e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CD—hematologic cancer	9.56e-07	8.32e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALB—hematologic cancer	9.44e-07	8.21e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3R1—hematologic cancer	9.03e-07	7.85e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CB—hematologic cancer	8.33e-07	7.25e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CA—hematologic cancer	7.77e-07	6.76e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CA—hematologic cancer	7.7e-07	6.7e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PTEN—hematologic cancer	7.2e-07	6.27e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—EP300—hematologic cancer	6.87e-07	5.97e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—AKT1—hematologic cancer	6.35e-07	5.52e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—AKT1—hematologic cancer	6.29e-07	5.47e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CA—hematologic cancer	5.08e-07	4.42e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—AKT1—hematologic cancer	4.15e-07	3.61e-05	CbGpPWpGaD
